Annual report pursuant to Section 13 and 15(d)

REVENUES - Disaggregated (Details)

v3.24.0.1
REVENUES - Disaggregated (Details) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Disaggregation of Revenue [Line Items]      
Total revenues $ 116,882,000 $ 120,242,000 $ 149,236,000
Gross product sales      
Disaggregation of Revenue [Line Items]      
Total revenues 147,058,000 108,523,000 81,186,000
Discounts and allowances      
Disaggregation of Revenue [Line Items]      
Total revenues (42,764,000) (31,805,000) (18,176,000)
Product sales, net      
Disaggregation of Revenue [Line Items]      
Total revenues 104,294,000 76,718,000 63,010,000
License revenues      
Disaggregation of Revenue [Line Items]      
Total revenues   7,932,000 70,553,000
Milestone      
Disaggregation of Revenue [Line Items]      
Total revenues 75,000 25,000,000 1,875,000
Delivery of drug supplies, royalty and others      
Disaggregation of Revenue [Line Items]      
Total revenues 11,413,000 6,092,000 3,298,000
Revenues from collaborations      
Disaggregation of Revenue [Line Items]      
Total revenues 11,488,000 39,024,000 75,726,000
Government contracts      
Disaggregation of Revenue [Line Items]      
Total revenues $ 1,100,000 $ 4,500,000 $ 10,500,000